{"id":"W4281666355","doi":"10.1200/jco.22.01003","title":"A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":384,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Sherbrooke","funders":"National Cancer Institute; Genentech; Eisai; National Institute for Health and Care Research; MacroGenics; Clovis Oncology; NuCana; Novocure; Puma Biotechnology; Regeneron Pharmaceuticals; Array BioPharma; EMD Serono; Mersana Therapeutics; Karyopharm Therapeutics; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Amgen; Pfizer","keywords":"Medicine; Population; Hazard ratio; Internal medicine; Ovarian cancer; Clinical endpoint; Placebo; Oncology; BRCA mutation; Surgery; Cancer; Clinical trial; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001427334,0.001079041,0.001944009,0.0004478031,0.0002840055,0.0007027153,0.0008168307,0.001305842,0.005477828],"category_scores_gemma":[0.001471957,0.0004725293,0.0009102949,0.0003568412,0.0007952519,0.0006685262,0.0003471454,0.00193011,0.0008170043],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006253335,"about_ca_system_score_gemma":0.0009424274,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007347192,"about_ca_topic_score_gemma":0.002279593,"domain_scores_codex":[0.9994757,0.0003272741,0.00002055424,0.00008812697,0.00003177543,0.00005652149],"domain_scores_gemma":[0.9992412,0.0002095231,0.0001929812,0.00006843447,0.00004498197,0.0002428069],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9683542,0.006667632,0.0006902568,0.0003080088,0.0005242391,0.00002957422,0.00003258834,0.0003163305,0.002929226,0.0001322347,0.001077699,0.01893811],"study_design_scores_gemma":[0.9351439,0.06217625,0.001254852,0.00001505277,0.0001817544,0.00002996605,0.000008939724,0.0003075942,0.0002234102,0.00008809193,0.0005636531,0.000006479649],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9825545,0.004791573,0.0007946767,0.00068377,0.0005078246,0.005964679,0.001446897,0.000137929,0.003118119],"genre_scores_gemma":[0.9798189,0.002217974,0.002383551,0.001541472,0.0005909142,0.007367109,0.002120057,0.00002508667,0.003934898],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005477828,"threshold_uncertainty_score":0.01832509,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1037382995368031,"score_gpt":0.4865092343933121,"score_spread":0.382770934856509,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}